| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| daunorubicin | dna topoisomerase 2-alpha | small molecule | NA | drugbank , DGIDB | Leukemia Myelocytic Acute[MeSHID:D015470] Monocytes[MeSHID:D009000] Diagnosis[MeSHID:D003933] Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] MYELODYSPLASTIC SYNDROME[MeSHID:D009190] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] Kaposi Sarcoma[MeSHID:D012514] |
0.09 | approved | inhibitor |
| daunorubicin | dna topoisomerase 2-beta | small molecule | NA | drugbank , DGIDB | Leukemia Myelocytic Acute[MeSHID:D015470] Monocytes[MeSHID:D009000] Diagnosis[MeSHID:D003933] Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] MYELODYSPLASTIC SYNDROME[MeSHID:D009190] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] Kaposi Sarcoma[MeSHID:D012514] |
0.07 | approved | inhibitor |
| daunorubicin | dna | small molecule | NA | drugbank | Leukemia Myelocytic Acute[MeSHID:D015470] Monocytes[MeSHID:D009000] Diagnosis[MeSHID:D003933] Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] MYELODYSPLASTIC SYNDROME[MeSHID:D009190] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] Kaposi Sarcoma[MeSHID:D012514] |
NA | approved | intercalation |
| click here to return to the previous page | ||||||||